LUNG CANCER

Pembrolizumab significantly improves survival rates in early-stage non-small cell lung cancer, establishing a new standard of care in perioperative therapy.

Sacituzumab tirumotecan significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer compared to traditional chemotherapy.

Zipalertinib shows promising efficacy in treating non-small cell lung cancer with CNS metastases, highlighting its potential as a new therapeutic option.

The DREAM3R trial explores durvalumab plus chemotherapy for advanced pleural mesothelioma, revealing promising survival rates despite early study limitations.

New findings reveal I-DXd's promising efficacy in treating extensive-stage small cell lung cancer with brain metastases, showcasing significant response rates.

The SKYSCRAPER-03 trial showed that consolidation tiragolumab plus atezolizumab does not improve progression-free survival in advanced lung cancer compared to durvalumab.

Tarlatamab-dlle shows significant overall survival benefits over chemotherapy in small cell lung cancer, even in platinum-resistant cases.

Combination therapy of osimertinib and chemotherapy significantly enhances overall survival in patients with EGFR-mutated advanced lung cancer, surpassing monotherapy outcomes.

Combining local consolidative therapy with osimertinib enhances progression-free survival in metastatic EGFR-mutant non-small cell lung cancer patients.

Alectinib shows promising long-term survival benefits over crizotinib in advanced ALK-positive lung cancer, highlighting significant clinical advancements.

Sevabertinib shows promising efficacy in treating HER2-mutant advanced NSCLC, achieving high response rates and durable outcomes in clinical trials.

Zongertinib shows promising results as a first-line treatment for advanced HER2-mutant NSCLC, achieving high response rates and significant clinical benefits.

An expert discusses how maintenance lurbinectedin benefits patients across subgroups, including those with liver metastases, and may be considered for patients with brain metastases after radiation therapy, while emphasizing the importance of patient counseling about continued chemotherapy expectations.

An expert discusses how maintenance lurbinectedin plus atezolizumab should be followed by standard second-line tarlatamab therapy at progression, as the maintenance approach doesn't change subsequent treatment sequencing.

A recent study reveals that systematic mediastinal lymph node dissection is unnecessary for stage T1 GGO-dominant lung adenocarcinoma, enhancing patient outcomes.

Julie Brahmer, MD, and David P. Carbone, MD, PhD, share insights on managing toxicities of immune checkpoint inhibitor therapies in non–small cell lung cancer.

An expert discusses how moving lurbinectedin to earlier in treatment is justified because 40% to 50% of patients with small cell lung cancer (SCLC) never receive second-line therapy due to rapid disease progression, making proactive treatment essential.

New trial data shows ivonescimab combined with chemotherapy significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer patients.

An expert discusses how lurbinectedin maintenance therapy causes primarily hematologic toxicities but has a low discontinuation rate (6.2%), making it suitable for most patients with good performance status and adequate blood count recovery.

Dr. Gerrina Ruiter discusses zongertinib's promising efficacy in treating HER2-mutant NSCLC, highlighting its unique effectiveness against brain metastases.

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with brain metastases.

New findings reveal zongertinib's effectiveness against brain metastases in HER2-mutant non–small cell lung cancer, offering hope for better treatment options.

Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians in the Treating Together podcast.

An expert discusses how the IMforte trial demonstrated that adding lurbinectedin to maintenance atezolizumab significantly improved progression-free survival (2.1 to 5.4 months) and overall survival (10.6 to 13.2 months) with an HR of 0.73.

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.